Filing Details
- Accession Number:
- 0001439222-23-000101
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-06-30 16:03:58
- Reporting Period:
- 2023-06-28
- Accepted Time:
- 2023-06-30 16:03:58
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1439222 | Agios Pharmaceuticals Inc. | AGIO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1840056 | Cecilia Jones | C/O Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge MA 02139 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-06-28 | 5,380 | $0.00 | 5,380 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-06-30 | 1,597 | $28.36 | 3,783 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Performance share units | Disposition | 2023-06-28 | 5,380 | $0.00 | 5,380 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
5,380 | No | 4 | M | Direct |
Footnotes
- Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units.
- Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
- The PSUs vest as to 50% of the underlying shares upon the achievement of a specified clinical milestone and as to 50% of the underlying shares upon the achievement of a specified research milestone. The performance criteria for the specified clinical milestone was determined to have been met on June 28, 2023, resulting in the vesting of the PSUs as to 50% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested.